Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial

Overall survival (OS) benefits of neoadjuvant immunotherapy remain elusive in locally advanced esophageal squamous cell carcinomas (ESCC). Here, we reported the results of a phase 1b trial of neoadjuvant PD-L1 blockade with adebrelimab in resectable ESCC. Patients received two neoadjuvant doses of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Jun, Yuan, Jingnan, Li, Yunjin, Fang, Yong, Wang, Ruoxi, Jiao, Heng, Tang, Han, Zhang, Shaoyuan, Lin, Siyun, Su, Feng, Gu, Jianmin, Jiang, Tian, Lin, Dong, Huang, Zhiliang, Du, Chaoxiang, Wu, Kui, Tan, Lijie, Zhou, Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427424/
https://www.ncbi.nlm.nih.gov/pubmed/37488287
http://dx.doi.org/10.1038/s41591-023-02469-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427424/
https://www.ncbi.nlm.nih.gov/pubmed/37488287
http://dx.doi.org/10.1038/s41591-023-02469-3

Ejemplares similares